ArticleJournal for immunotherapy of cancer2019

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).

Jean-Pascal Machiels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.